• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

散发性和地方性 Burkitt 淋巴瘤有频繁的突变,但在 AKT 识别基序中有不同的热点。

Sporadic and endemic Burkitt lymphoma have frequent mutations but distinct hotspots in the AKT recognition motif.

机构信息

Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.

Department of Paediatrics, College of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.

出版信息

Blood Adv. 2019 Jul 23;3(14):2118-2127. doi: 10.1182/bloodadvances.2018029546.

DOI:10.1182/bloodadvances.2018029546
PMID:31300419
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6650741/
Abstract

FOXO1 has an oncogenic role in adult germinal center-derived lymphomas, in which mutations, predominately within the AKT recognition motif, cause nuclear retention of FOXO1, resulting in increased cell proliferation. To determine the prevalence and distribution of mutations in pediatric Burkitt lymphoma (BL), we sequenced a large number of sporadic and endemic BL patient samples. We report a high frequency of mutations in both sporadic and endemic BL at diagnosis, occurring in 23/78 (29%) and 48/89 (54%) samples, respectively, as well as 8/16 (50%) cases at relapse. Mutations of T24 were the most common in sporadic BL but were rare in endemic cases, in which mutations of residue S22, also within the AKT recognition motif, were the most frequent. mutations were almost always present in the major tumor cell clone but were not associated with outcome. Analysis of other recurrent mutations reported in BL revealed that mutations were associated with mutations of and but not , / or members of the phosphatidylinositol 3-kinase signaling pathway. We further show common nuclear retention of the FOXO1 protein, irrespective of mutation status, suggesting alternative unknown mechanisms for maintaining FOXO1 transcriptional activity in BL. CRISPR/Cas9 knockout of in an endemic cell line produced a significant decrease in cell proliferation, supporting an oncogenic role for in endemic BL. Thus, is frequently mutated in both sporadic and endemic BL and may offer a potential therapeutic target for pediatric BL patients worldwide.

摘要

FOXO1 在成人生发中心衍生的淋巴瘤中具有致癌作用,其中突变主要发生在 AKT 识别基序内,导致 FOXO1 的核内滞留,从而导致细胞增殖增加。为了确定儿童伯基特淋巴瘤(BL)中突变的流行率和分布,我们对大量散发性和地方性 BL 患者样本进行了测序。我们报告了在散发性和地方性 BL 诊断时 突变的高频发生,分别在 23/78(29%)和 48/89(54%)样本中,以及在 8/16(50%)复发病例中。T24 突变在散发性 BL 中最为常见,但在地方性病例中很少见,在 AKT 识别基序内的 S22 残基突变最为常见。 突变几乎总是存在于主要肿瘤细胞克隆中,但与结局无关。对 BL 中报道的其他反复发生的突变的分析表明, 突变与 和 突变有关,但与 、 或磷脂酰肌醇 3-激酶信号通路的成员无关。我们进一步表明,无论突变状态如何,FOXO1 蛋白的常见核内滞留提示 BL 中维持 FOXO1 转录活性的替代未知机制。CRISPR/Cas9 敲除地方性细胞系中的 会导致细胞增殖显著减少,支持 在地方性 BL 中的致癌作用。因此, 在散发性和地方性 BL 中经常发生突变,可能为全球儿童 BL 患者提供潜在的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/592f/6650741/29103b0af31e/advances029546absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/592f/6650741/29103b0af31e/advances029546absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/592f/6650741/29103b0af31e/advances029546absf1.jpg

相似文献

1
Sporadic and endemic Burkitt lymphoma have frequent mutations but distinct hotspots in the AKT recognition motif.散发性和地方性 Burkitt 淋巴瘤有频繁的突变,但在 AKT 识别基序中有不同的热点。
Blood Adv. 2019 Jul 23;3(14):2118-2127. doi: 10.1182/bloodadvances.2018029546.
2
Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.散发性伯基特淋巴瘤的 Epstein-Barr 病毒状态与患者年龄和突变特征相关。
Br J Haematol. 2022 Feb;196(3):681-689. doi: 10.1111/bjh.17874. Epub 2021 Oct 6.
3
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.核 FOXO1 促进生发中心 B 细胞淋巴瘤的发生。
Blood. 2018 Dec 20;132(25):2670-2683. doi: 10.1182/blood-2018-06-856203. Epub 2018 Oct 17.
4
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.从结构和功能基因组学角度探讨伯基特淋巴瘤的发病机制和治疗靶点。
Nature. 2012 Oct 4;490(7418):116-20. doi: 10.1038/nature11378. Epub 2012 Aug 12.
5
The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.具有 11q 异常的伯基特样淋巴瘤的突变景观与伯基特淋巴瘤不同。
Blood. 2019 Feb 28;133(9):962-966. doi: 10.1182/blood-2018-07-864025. Epub 2018 Dec 19.
6
B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.EBV 阳性伯基特淋巴瘤中 B 细胞分化在转录后水平受到 miRNA 表达改变的损害。
Int J Cancer. 2010 Mar 15;126(6):1316-26. doi: 10.1002/ijc.24655.
7
Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes.视网膜母细胞瘤相关基因RB2/p130的基因改变揭示了伯基特淋巴瘤各亚型及其之间不同的致病机制。
Am J Pathol. 2000 Mar;156(3):751-60. doi: 10.1016/s0002-9440(10)64941-3.
8
Burkitt lymphoma-related mutations alter TCF3 alternative splicing by disrupting hnRNPH1 binding.Burkitt 淋巴瘤相关突变通过破坏 hnRNPH1 结合来改变 TCF3 的可变剪接。
RNA Biol. 2020 Oct;17(10):1383-1390. doi: 10.1080/15476286.2020.1772559. Epub 2020 Jun 4.
9
Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.在儿科地方性和散发型伯基特淋巴瘤中发现全基因组体细胞编码和非编码突变。
Blood. 2019 Mar 21;133(12):1313-1324. doi: 10.1182/blood-2018-09-871418. Epub 2019 Jan 7.
10
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.IGH-BCL2 和 MYC 同时重排的 B 细胞淋巴瘤是具有侵袭性的肿瘤,其临床和病理特征与 Burkitt 淋巴瘤和弥漫性大 B 细胞淋巴瘤不同。
Am J Surg Pathol. 2010 Mar;34(3):327-40. doi: 10.1097/PAS.0b013e3181cd3aeb.

引用本文的文献

1
Genomic landscape of virus-associated cancers.病毒相关癌症的基因组图谱。
Nat Commun. 2025 Jul 1;16(1):5887. doi: 10.1038/s41467-025-60836-9.
2
Mutant FOXO1 controls an oncogenic network via enhancer accessibility.突变 FOXO1 通过增强子可及性控制致癌网络。
Cell Genom. 2024 Apr 10;4(4):100537. doi: 10.1016/j.xgen.2024.100537.
3
Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal Tissues.儿童第二恶性肿瘤的起源和正常组织中化疗的突变足迹。

本文引用的文献

1
Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.在儿科地方性和散发型伯基特淋巴瘤中发现全基因组体细胞编码和非编码突变。
Blood. 2019 Mar 21;133(12):1313-1324. doi: 10.1182/blood-2018-09-871418. Epub 2019 Jan 7.
2
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.核 FOXO1 促进生发中心 B 细胞淋巴瘤的发生。
Blood. 2018 Dec 20;132(25):2670-2683. doi: 10.1182/blood-2018-06-856203. Epub 2018 Oct 17.
3
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.
Cancer Discov. 2024 Jun 3;14(6):953-964. doi: 10.1158/2159-8290.CD-23-1186.
4
The discrete roles of individual FOXO transcription factor family members in B-cell malignancies.个体 FOXO 转录因子家族成员在 B 细胞恶性肿瘤中的离散作用。
Front Immunol. 2023 May 18;14:1179101. doi: 10.3389/fimmu.2023.1179101. eCollection 2023.
5
The transcriptional program during germinal center reaction - a close view at GC B cells, Tfh cells and Tfr cells.生发中心反应期间的转录程序——GC B 细胞、Tfh 细胞和 Tfr 细胞的近距离观察。
Front Immunol. 2023 Feb 3;14:1125503. doi: 10.3389/fimmu.2023.1125503. eCollection 2023.
6
Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia.急性淋巴细胞白血病中染色体 6 缺失导致 FOXO-PRDM1 轴的破坏。
Leukemia. 2023 Mar;37(3):636-649. doi: 10.1038/s41375-023-01816-0. Epub 2023 Jan 20.
7
A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas.FOXO1 依赖性转录网络是套细胞淋巴瘤的一个可靶向弱点。
J Clin Invest. 2022 Dec 15;132(24):e160767. doi: 10.1172/JCI160767.
8
Minimal information for reporting a genomics experiment.基因组实验报告的最低信息要求。
Blood. 2022 Dec 15;140(24):2549-2555. doi: 10.1182/blood.2022016095.
9
Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma.遗传亚群为成人和儿童伯基特淋巴瘤的病理生物学提供信息。
Blood. 2023 Feb 23;141(8):904-916. doi: 10.1182/blood.2022016534.
10
Oncogenic Mutations in the DNA-Binding Domain of FOXO1 that Disrupt Folding: Quantitative Insights from Experiments and Molecular Simulations.FOXO1 DNA 结合域致瘤突变导致蛋白折叠异常:实验和分子模拟的定量分析。
Biochemistry. 2022 Aug 16;61(16):1669-1682. doi: 10.1021/acs.biochem.2c00224. Epub 2022 Jul 27.
FOXO1促进非霍奇金淋巴瘤对基于抗CD20治疗的耐药性。
Oncoimmunology. 2018 Jan 25;7(5):e1423183. doi: 10.1080/2162402X.2017.1423183. eCollection 2018.
4
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤的遗传学与发病机制
N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.
5
Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management.评估基于捕获和扩增子的方法,以开发针对淋巴瘤管理的个体化靶向下一代测序管道。
J Mol Diagn. 2018 Mar;20(2):203-214. doi: 10.1016/j.jmoldx.2017.11.010. Epub 2018 Feb 8.
6
FOXOs in cancer immunity: Knowns and unknowns.FOXOs 在癌症免疫中的作用:已知和未知。
Semin Cancer Biol. 2018 Jun;50:53-64. doi: 10.1016/j.semcancer.2018.01.005. Epub 2018 Jan 5.
7
Re-evaluating the role of FOXOs in cancer.重新评估 FOXOs 在癌症中的作用。
Semin Cancer Biol. 2018 Jun;50:90-100. doi: 10.1016/j.semcancer.2017.11.017. Epub 2017 Nov 21.
8
Selective Inhibition of FOXO1 Activator/Repressor Balance Modulates Hepatic Glucose Handling.FOXO1激活剂/阻遏物平衡的选择性抑制调节肝脏葡萄糖代谢。
Cell. 2017 Nov 2;171(4):824-835.e18. doi: 10.1016/j.cell.2017.09.045. Epub 2017 Oct 19.
9
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.弥漫性大B细胞淋巴瘤的遗传和功能驱动因素
Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.
10
Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.将弥漫性大 B 细胞淋巴瘤中的基因组改变进行整合,可鉴定出新的相关途径和潜在的治疗靶点。
Leukemia. 2018 Mar;32(3):675-684. doi: 10.1038/leu.2017.251. Epub 2017 Aug 14.